Maravai Lifesciences (MRVI) said Wednesday it expects to report 2024 revenue near the mid-point of its guidance range of $255 million to $265 million.
Analysts polled by FactSet expect $259.8 million.
The company said it will release its Q4 and full-year 2024 results after the market close on Feb. 25.
Maravai shares were falling 3.4% in recent after-hours trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.